Decoy Therapeutics Broadens Patent Portfolio for Designable Multi-Antivirals and IMP³ACT™ Platform

Decoy Therapeutics Inc., a biotechnology company specializing in Designable Multi-Antivirals (D-MAVs™), announced on August 3, 2026, a significant expansion of its intellectual property portfolio. The company’s portfolio now includes seven patent families with 19 pending applications filed across seven jurisdictions: the United States, Australia, Canada, China, Europe, Japan, and New Zealand. All patents and applications are solely owned by Decoy.

The expanded portfolio protects a broad spectrum of innovations, including compositions of matter, methods of manufacture, formulations, and the proprietary IMP³ACT™ design platform. This platform integrates artificial intelligence-enabled design with rapid synthesis to develop peptide antivirals aimed at addressing a wide range of viral infections.

Rick Pierce, Chief Executive Officer of Decoy Therapeutics, emphasized the correlation between the company’s scientific progress and its intellectual property growth. He stated, "Our IP position has grown alongside the science. The early filings protected our first conjugates. The newer families protect the engineered sequences our platform now designs, the methods we use to make them, and the platform itself. That progression is one of the clearest external record of how far the technology has come."

Among the granted patents, U.S. Patent No. 12,226,474 titled "Methods and Compositions for Treating Infections" claims antiviral peptide conjugates composed of one or more viral spike protein sequences incorporating D-amino acids. This patent underpins the company’s foundational antiviral compositions.

The portfolio also includes a broadly filed patent family titled "Methods for Making Peptide Conjugates and the Product Made Therefrom," which covers automated flow peptide synthesis methods and linker chemistries used in producing Decoy’s antiviral peptide conjugates. This family is pending in six jurisdictions outside the United States.

Further patent families focus on engineered D-MAVs. The "New Antiviral Therapeutic Peptides, Conjugates and Methods of Use Thereof" filings cover compounds designed to target conserved features of class I viral fusion proteins, extending beyond wild-type peptide sequences. Companion filings protect formulations containing these conjugates and their use in interrupting viral transmission, including against paramyxoviruses such as measles, mumps, human parainfluenza virus, and Nipah virus.

Decoy’s most recent filing, submitted in June 2026 and not yet published, is titled "Method of Designing New Class I Fusion Peptides and Therapeutics Made Thereof." This application protects the design methods integral to the IMP³ACT platform.

Decoy Therapeutics is pioneering a new category of antivirals engineered to target shared viral mechanisms, enabling a single adaptable drug to combat multiple viruses. The company’s lead candidates focus on respiratory viruses, aiming to reduce the health and societal impact of viral diseases.

The company’s press release includes standard forward-looking statements under the Private Securities Litigation Reform Act of 1995, cautioning that actual results may differ due to risks such as the potential non-grant of patent applications, financing challenges, and development uncertainties related to IND applications and the IMP³ACT platform.

Decoy’s expanding patent portfolio underscores its commitment to advancing antiviral therapeutics through innovative design and manufacturing technologies, positioning the company at the forefront of viral prevention and treatment research.